ArticleFrontiers in medicine2026
PruDensNet: a parameter efficient depthwise separable CNN for MRI-based brain tumor classification.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study introduces PruDensNet, a parameter-efficient, depthwise-separable convolutional network for magnetic resonance imaging (MRI)-based brain-tumor classification, motivated by compute and latency-sensitive deployments where efficiency can improve throughput and cost. The architecture integrates lightweight channel and spatial attention with Gaussian Error Linear Unit (GELU) activations and a compact global average pooling (GAP)-Dense head, totaling approximately 1.46 M parameters. Architectural effects are isolated from capacity by equalizing parameter budgets across baselines through a no-operation padding mechanism. A reproducible curation pipeline standardizes labels, removes near-duplicates, and applies a stratified split. Training follows a curriculum-regularized recipe combining MixUp, CutMix, random erasing, CLAHE, and label smoothing, with AdamW optimization, warmup-cosine decay, gradient clipping, mixed precision, and test-time augmentation. On a four-class Brain Tumor MRI benchmark (glioma, meningioma, pituitary, no tumor), PruDensNet attains test accuracy 96.05% and validation accuracy 97.27% with competitive per-class metrics, outperforming matched-capacity Convolutional Neural Network (CNN) and Transformer baselines. The results indicate a favorable accuracy-footprint trade-off that can support cost- and latency-sensitive clinical workflows, subject to external validation and hardware-specific benchmarking.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.